Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Bioconjugate Chemistry|June 1, 2018
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 InhibitionHonorine Lebraud, Richard A Noble, Nicole Phillips, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767Noel R Monks, David C Blakey, Simon J East, et al.
Biochemical Pharmacology|May 12, 2009
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2Luke R E Harrison, Christopher J Ottley, D Graham Pearson, et al.
NMR in Biomedicine|May 26, 2017
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRSGilberto S Almeida, Carlo M Bawn, Martin Galler, et al.
Organic & Biomolecular Chemistry|April 11, 2015
Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatasesDuncan C Miller, Benoit Carbain, Gary S Beale, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, et al.
Plos One|December 17, 2013
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing miceEmma J Haagensen, Huw D Thomas, Ian Wilson, et al.
Cell Cycle (Georgetown, Tex.)|March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferationPamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
British Journal of Clinical Pharmacology|February 19, 2002
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposideHuw D Thomas, David J Porter, Imke Bartelink, et al.
Haematologica|January 19, 2019
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIMElizabeth C Matheson, Huw Thomas, Marian Case, et al.
Pageof 8